Kura Oncology (NASDAQ:KURA) Announces Earnings Results

Kura Oncology (NASDAQ:KURA) released its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.43, Zacks reports.

Kura Oncology Stock Performance

Shares of Kura Oncology stock traded down $0.11 on Wednesday, reaching $7.77. 695,635 shares of the company traded hands, compared to its average volume of 1,618,769. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm has a market capitalization of $604.23 million, a PE ratio of -3.29 and a beta of 0.78. The company has a 50 day moving average of $8.22 and a 200 day moving average of $13.96. Kura Oncology has a 52 week low of $6.98 and a 52 week high of $24.17.

Analyst Ratings Changes

KURA has been the topic of a number of analyst reports. Jefferies Financial Group lowered their target price on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. JMP Securities reiterated a “market outperform” rating and set a $28.00 price target on shares of Kura Oncology in a report on Thursday, February 6th. TD Cowen reissued a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Finally, HC Wainwright lifted their price objective on shares of Kura Oncology from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $27.13.

Insider Activity at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,729 shares of company stock worth $92,307. Insiders own 5.50% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.